Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL-37807
- Development stage
- Phase 2
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
AL-37807 is a small molecule drug developed as an ophthalmic solution for the treatment of open-angle glaucoma and ocular hypertension. It was originally developed by Alcon, which later became part of Novartis. The drug acts as a 5-hydroxytryptamine (5-HT) receptor agonist, representing a novel mechanism among antiglaucoma agents. Its development reached Phase II clinical trials in the United States but was discontinued before approval. The primary aim was to lower intraocular pressure in patients with glaucoma or ocular hypertension.
- Other names
- AL-37807 Ophthalmic SuspensionAL37807 Ophthalmic SuspensionAL 37807 Ophthalmic Suspension
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on AL-37807.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL-37807.